ICYMI: PharmaCyte Biotech’s New Weapon Against Pancreatic Cancer: Cell-in-a-Box® 
source: pixabay.com

ICYMI: PharmaCyte Biotech’s New Weapon Against Pancreatic Cancer: Cell-in-a-Box® 

  Cell-in-a-Box, the name of one of Biotech’s new products is just as intriguing as the drug itself. A recent article in NewsFile characterizes the product as having the potential…

Continue Reading ICYMI: PharmaCyte Biotech’s New Weapon Against Pancreatic Cancer: Cell-in-a-Box® 
First Treatment for Transthyretin Amyloidosis Cardiomyopathy Approved in Europe
source: pixabay.com

First Treatment for Transthyretin Amyloidosis Cardiomyopathy Approved in Europe

As originally reported in Pfizer, the European Commission has just approved the first treatment option ever available to treat transthyretin amyloidosis cardiomyopathy (ATTR-CM). The medication, VYNDAQEL, taken orally once daily,…

Continue Reading First Treatment for Transthyretin Amyloidosis Cardiomyopathy Approved in Europe
ICYMI: Privigen Granted Orphan Drug Designation For Treatment of Systemic Scleroderma
source: pixabay.com

ICYMI: Privigen Granted Orphan Drug Designation For Treatment of Systemic Scleroderma

CSL Behring has recently received the Orphan Drug designation for Privigen for the treatment of systemic scleroderma. Privigen has also been granted the Fast Track designation. This therapy has been…

Continue Reading ICYMI: Privigen Granted Orphan Drug Designation For Treatment of Systemic Scleroderma
Priority Review Granted for Relapsed and Refractory Follicular Lymphoma Treatment
source: pixabay.com

Priority Review Granted for Relapsed and Refractory Follicular Lymphoma Treatment

According to a press release from Epizyme, Priority Review has been granted for tazemetostat (Tazverik), a drug used to treat relapsed or refractory follicular lymphoma (FL) for patients whose symptoms…

Continue Reading Priority Review Granted for Relapsed and Refractory Follicular Lymphoma Treatment

The EMA Grants PRIME Designation to Viralym-M To Treat Viral Infections Linked to Stem Cell Transplant

  According to a recent article in The Pharma Letter, the European Medicines Agency (EMA) granted PRIME (PRIority MEdicines) designation to Viralym-M based on positive results from a Phase 2 proof-of-concept…

Continue Reading The EMA Grants PRIME Designation to Viralym-M To Treat Viral Infections Linked to Stem Cell Transplant
Toxic Protein Identified: Closing in on Alzheimer’s and Neurodegenerative Diseases
source: pixabay.com

Toxic Protein Identified: Closing in on Alzheimer’s and Neurodegenerative Diseases

  For years scientists have tried to understand how and why tau, well known to researchers for its implication in Alzheimer’s disease, changes from its normal form to a harmful…

Continue Reading Toxic Protein Identified: Closing in on Alzheimer’s and Neurodegenerative Diseases
Specific Autoantibodies Linked to Scleroderma, Research Study Finds
source: pixabay.com

Specific Autoantibodies Linked to Scleroderma, Research Study Finds

By Jodee Redmond from In The Cloud Copy A recent study suggests that certain antibodies could be linked to specific human leukocyte antigen (HLA) genes and environmental components in scleroderma.…

Continue Reading Specific Autoantibodies Linked to Scleroderma, Research Study Finds
Genetic Difference Found Between Type 1 Diabetes and Latent Autoimmune Diabetes of Adulthood (LADA)
source: pixabay.com

Genetic Difference Found Between Type 1 Diabetes and Latent Autoimmune Diabetes of Adulthood (LADA)

By Natalie Homan from In the Cloud Copy Most people have heard of type 1 and type 2 diabetes. Many do not know, however, that there is an “intermediate” form…

Continue Reading Genetic Difference Found Between Type 1 Diabetes and Latent Autoimmune Diabetes of Adulthood (LADA)
The Increasing Role of PARP Inhibitors for the Treatment of Ovarian Cancer
source: pixabay.com

The Increasing Role of PARP Inhibitors for the Treatment of Ovarian Cancer

Poly ADP-ribose polymerase (PARP) inhibitors have played an increasing role in the treatment of ovarian cancer. They are being very heavily studied in clinical trials, both for the treatment of…

Continue Reading The Increasing Role of PARP Inhibitors for the Treatment of Ovarian Cancer
Elderly Patients with Myelodysplastic Syndromes can Have Successful Transplants
source: pixabay.com

Elderly Patients with Myelodysplastic Syndromes can Have Successful Transplants

By Rachel Whetstone from In The Cloud Copy Many patients with myelodysplastic syndromes (MDS) are elderly when they’re diagnosed with the disease. Although stem cell transplants are often thought to…

Continue Reading Elderly Patients with Myelodysplastic Syndromes can Have Successful Transplants
Close Menu